- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Vaccine development

Vaccinations are a crucial health intervention to prevent infectious diseases. Our research into how the immune system responds to infections is improving the development of vaccines for globally significant diseases.
Our research into vaccines
Our researchers strive to understand how vaccines trigger immune responses that protect against infections, and develop new vaccines for significant diseases.
Our vaccine research benefits from our researchers’ expertise in infectious diseases and how long-term immunity to infections develops.
An important goal of our research is to develop and test vaccines for malaria.
What are vaccines?
Vaccines are preparations that stimulate protective immune responses against an infection or toxin, using a harmless component, or weakened form of the infectious agent or toxin. For example, most current vaccines stimulate the production of immune proteins called antibodies that specifically neutralise the particular infection or toxin against which the vaccine has been made.
Vaccines can take several forms. They may be:
- Killed microbes of the type that, when alive, cause illness.
- A weakened form of the microbe, or a related microbe, that causes less severe infection.
- A purified component of the microbe, such as a particular protein or carbohydrate, that triggers protective immunity.
Some vaccines also contain substances, called adjuvants, that boost the immune response.
Most vaccines are given as injections, introducing the vaccine into a muscle or a layer of the skin. Some vaccines, particularly for infections that enter the body through the digestive tract, are given orally. The route of delivery of a vaccine influences the characteristics of the protective immunity that is developed.
How are vaccines developed?
There are many pre-clinical stages of research before a vaccine for a disease can be developed. This research addresses questions including:
- Do humans normally develop protective immunity against the infection? This increases the chances of making a successful vaccine.
- Which proteins or carbohydrates in the microbe can immune cells respond to? Are there different versions of these proteins or carbohydrates in the microbe?
- Can the immune-stimulating components of the microbe be packaged in vaccine form, and delivered into experimental systems to stimulate immune responses?
- Do the immune responses prevent subsequent infection with the microbe, and how long does the protection last?
- How can large amounts of the vaccine be prepared in a consistent and cost-efficient way? A vaccine that is labour-intensive to make, or can only be made in small batches, may not be economically feasible.
If a vaccine shows promise in pre-clinical testing, it may enter clinical trials. These involve giving the vaccine to volunteers to test:
- The safety of the vaccine and highest dose tolerated.
- Whether people develop the expected immune changes after being given the vaccine.
- Whether people at risk of infection with the target microbe are protected by the vaccine.
These steps can take many years. If a vaccine is shown to be safe, and beneficial for protecting people against infection, it may be approved by government bodies for clinical use.
Depending on the prevalence and severity of the infection in a community, the vaccine may be recommended:
- For all people, such as measles vaccine, to restrict any transmission of the infection in the community.
- For people who are likely to be exposed to the infection. Cholera vaccinations for travellers visiting parts of the world where this disease is prevalent are an example.
- For people who are at high risk of serious illness caused by an infection that is less severe in most people. For example, people with chronic respiratory diseases are advised to have flu vaccines.
Vaccine safety
All vaccines available for use in humans are thoroughly assessed for safety by independent health authorities and researchers. Vaccines are only approved for use if they are proven to be beneficial in protecting against a potentially serious infection.
In some cases, rare side-effects can occur in a small number of people who receive a vaccine. These are typically less serious, and much less likely than potential side-effects of the infection the vaccine aims to protect against
When a vaccine is recommended for a person, it is because any risk of receiving the vaccine is outweighed by the risk of not being vaccinated and contracting the relevant infection.
The Australian Academy of Science’s The Science of Immunisation booklet provides scientifically valid answers to many of the frequently asked questions about vaccination and vaccine safety.
Switching off immune responses
Usually vaccination refers to treatments that trigger immune responses. Some vaccines are being developed that switch off harmful immune responses.
An example is a nasal insulin spray developed by our researchers that is now in clinical trials for preventing type 1 diabetes in susceptible people. The treatment is being tested for its ability to turn off the harmful immune responses to insulin-secreting pancreatic cells that cause type 1 diabetes.
Researchers:
Super Content:
We have developed the first malaria vaccine that can be tailored to match many different strains of malaria.
What new discoveries and treatments are on the horizon for infectious diseases? Catch up with the discussion from this public talk.
Our researchers have defined for the first time how the size of the immune response is controlled during infection, or in response to vaccination.
We are a member of the Asia Pacific Malaria Elimination Network (APMEN), an international collaborative network working towards eliminating malaria in the Asia-Pacific region.